Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia

European Journal of Clinical Pharmacology

Volumn 62, Issue 3, 2006, Pages 179-184

  Yang, Tian Lun ^a   Chen, Mei Fang ^a   Xia, Xin ^a   Luo, Bai Lin ^a   Li, Yuan Jian ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine (ADMA); Endothelial function; Fenofibrate; Nitric oxide (NO); Tumor necrosis factor (TNF )

Indexed keywords

FENOFIBRATE; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; VASODILATATION;

ADULT; ANTICHOLESTEREMIC AGENTS; ARGININE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CHOLESTEROL; CHOLESTEROL, HDL; DIET; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; PROCETOFEN; TREATMENT OUTCOME; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 33644817175     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0095-6     Document Type: Article

References (38)

1. Leiper J, Vallance P (1999) Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43:542-548
2. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33:652-658
3. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, Okumura K (2003) High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 18:177-182
4. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I (2003) Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166:279-284
5. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141-1146
6. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24:1912-1919
7. Boger RH (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59:824-833
8. Okopien B, Cwalina L, Haberka M, Kowalski J, Zielinski M, Szwed Z, Kalina Z, Herman ZS (2002) Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia. Pol Merkuriusz Lek 13:465-469
9. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR, DAIS Group (2003) Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733-1737
10. Liang B, McMaster JC, Kroeger EA, Hatch GM, Mymin D, Dembinski T, Arthur G, Shen G, Man RY, Choy PC (2000) The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients. Mol Cell Biochem 207:123-129
11. Yang TL, Chen MF, Luo BL, Yu J, Jiang JL, Li YJ (2004) Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schmiedeberg's Arch Pharmacol 370:79-83
12. Chen BM, Xia LW, Zhao RQ (1997) Determination of N(G),N (G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci 692:467-471
13. Bessman JD, Gardner FH (1983) Platelet size in thrombocytopenia due to sepsis. Surg Gynecol Obstet 156:177-180
14. Feng Q, Lu X, Jones DL, Shen J, Arnold JM (2001) Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104:700-704
15. Teppo AM, Maury CP (1987) Radioimmunoassay of tumor necrosis factor in serum. Clin Chem 33:2024-2027
16. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115
17. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032-2037
18. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP (2003) Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108:933-938
19. Paiva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R (2003) Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 41:219-222
20. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ (2000) Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 20:2039-2044
21. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P (2001) Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38:111-116
22. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127-2128
23. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264-6271
24. Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, Vallance P, McDonald N (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 8:679-683
25. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092-3095
26. Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, Handelman GJ, Barbato D, Weitzel W, D'Alecy LG, Rajagopalan S (2003) Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 18:2415-2420
27. Jiang JL, Li Ns NS, Li YJ, Deng HW (2002) Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 135:1175-1182
28. Jiang DJ, Jiang JL, Tan GS, Du YH, Xu KP, Li YJ (2003) Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn Schmiedebergs Arch Pharmacol 367:600-606
29. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S- adenosylmethionine-dependent methyltransferases. Circ Res 87:99-105
30. Sydow K, Schwedhelm E, Arakawa N et al (2003) ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 57:244-252
31. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP (2000) Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 20:1040-1046
32. Cybulsky MI, Gimbrone MA (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788-791
33. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP (2000) An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36:2287-2295
34. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J (2001) Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res 52:290-298
35. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143-151
36. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999) PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131
37. Dierkes J, Westphal S, Martens-Lobenhoffer J, Luley C, Bode-Boger SM (2004) Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. Atherosclerosis 173:239-244
38. Yang TL, Chen MF, Luo BL, Xie QY, Li YJ (2005) Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedeberg's Arch Pharmacol 371:401-407